Jump to navigation Jump to search


Stamulumab (MYO-029[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy. MYO-029 was formulated and tested by Wyeth in Collegeville, PA.[2] Myostatin is a protein that inhibits the growth of muscle tissue, MYO-029 is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]

Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy[4]

Phase 1 and 2 Trials


  • ACVR2B is similar to Stamulumab but is not an antibody; rather, it provides a portion of the molecule to which myostatin would normally bind thus preventing the myostatin from binding with the actual molecule[7].



Template:Muscular Dystrophy